- Home
- SRBK vs AFMD Comparison
SRBK vs AFMD Comparison
Compare SRBK & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRBK
- AFMD
- Stock Information
- Founded
- SRBK 1887
- AFMD 2000
- Country
- SRBK United States
- AFMD Germany
- Employees
- SRBK N/A
- AFMD N/A
- Industry
- SRBK
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- SRBK
- AFMD Health Care
- Exchange
- SRBK Nasdaq
- AFMD Nasdaq
- Market Cap
- SRBK 96.1M
- AFMD 53.3M
- IPO Year
- SRBK N/A
- AFMD 2014
- Fundamental
- Price
- SRBK $10.67
- AFMD $3.36
- Analyst Decision
- SRBK
- AFMD Strong Buy
- Analyst Count
- SRBK 0
- AFMD 5
- Target Price
- SRBK N/A
- AFMD $16.25
- AVG Volume (30 Days)
- SRBK 20.6K
- AFMD 80.0K
- Earning Date
- SRBK 01-01-0001
- AFMD 11-12-2024
- Dividend Yield
- SRBK N/A
- AFMD N/A
- EPS Growth
- SRBK N/A
- AFMD N/A
- EPS
- SRBK N/A
- AFMD N/A
- Revenue
- SRBK $22,814,000.00
- AFMD $7,959,927.00
- Revenue This Year
- SRBK N/A
- AFMD N/A
- Revenue Next Year
- SRBK N/A
- AFMD $48.98
- P/E Ratio
- SRBK N/A
- AFMD N/A
- Revenue Growth
- SRBK 52.54
- AFMD N/A
- 52 Week Low
- SRBK $8.01
- AFMD $2.92
- 52 Week High
- SRBK $11.24
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- SRBK 51.76
- AFMD 44.84
- Support Level
- SRBK $10.97
- AFMD $3.28
- Resistance Level
- SRBK $11.09
- AFMD $3.51
- Average True Range (ATR)
- SRBK 0.06
- AFMD 0.17
- MACD
- SRBK -0.05
- AFMD 0.04
- Stochastic Oscillator
- SRBK 5.50
- AFMD 55.79
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.